Lancet accuses AstraZeneca of sponsoring biased researchBMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7422.1005-a (Published 30 October 2003) Cite this as: BMJ 2003;327:1005
View Full Text
- Owen Dyer
The Lancet last week took the unprecedented step of accusing Europe's second biggest drug company, AstraZeneca, of sponsoring biased research into its new anticholesterol drug rosuvastatin (Crestor).
In an editorial, the journal's editor, Richard Horton, said the company's tactics “raise disturbing questions about how drugs enter clinical practice and what measures exist to protect patients from inadequately investigated medicines”(Lancet 2003;362: 1341).
The Galaxy series …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.